Skip to content
Optellum
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales
Menu Close
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

News & Events

GE Healthcare-Optellum’s collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel’s Mammoscreen

  • Post author:Rhiannon Lassiter
  • Post published:November 30, 2021
  • Post category:Media

Delve Insight

Read more articles

Previous PostGE Healthcare signs AI-focused cancer technology collaborations
Next PostGE Healthcare Announces Three New Alliances to Help Improve Cancer Care

You Might Also Like

Read more about the article Lung health startup partners with Johnson & Johnson’s lung cancer initiative

Lung health startup partners with Johnson & Johnson’s lung cancer initiative

August 18, 2021
Read more about the article Top Story GE Healthcare, Optellum partner up for AI-driven lung cancer diagnosis

Top Story GE Healthcare, Optellum partner up for AI-driven lung cancer diagnosis

November 26, 2021
Read more about the article Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson applying AI to transform early lung cancer treatment

Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson applying AI to transform early lung cancer treatment

August 20, 2021
  • Back to News & Events

Recent Posts

  • AtlantiCare First in Northeast to Deploy Optellum AI Alongside Robotics for Early Lung Cancer Diagnosis and Treatment
  • Jason Pesterfield, Optellum CEO, appears on Houston Innovators podcast
  • 150 most promising digital health companies of 2022, according to CB Insights
  • Lung Cancer Awareness Month: Optellum’s AI platform demonstrates a vital role in efficient diagnosis to improve lung cancer survival rates
  • Pulmonary advances and clinical collaborations at CHEST 2022

Our Mission

Optellum was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, and cured.  Our vision is to redefine early intervention of diseases like lung cancer, by enabling every clinician, in every hospital, to make the right decisions and give their patients the best chance to fight back.

Optellum Ltd.

  • Oxford Centre for Innovation
    Oxford, OX1 1BY
    United Kingdom
  • info@optellum.comOpens in your application

Optellum Inc.

  • TMC Innovation Institute
    2450 Holcombe Blvd, Suite X
    Houston, TX 77021
    United States

Pages

  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case Studies
    • Clinical Validation
    • Reimbursement
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

Follow Us

  • Opens in a new tab
  • Opens in a new tab

Certifications

Copyright 2023 - Optellum Ltd | Privacy Policy
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}